Core Viewpoint - The company plans to dispose of part of its shares in Beijng Beilu Pharmaceutical Co., Ltd. to enhance asset liquidity and focus on core business development [1][2]. Group 1: Stock Disposal Details - The company intends to sell up to 10 million shares of Beijng Beilu Pharmaceutical within three months after the pre-disclosure announcement of the reduction plan [1]. - As of the latest update, the company has sold 3 million shares of Beijng Beilu Pharmaceutical at an average price of approximately 10.22 CNY per share, totaling a transaction amount of 30,665,658 CNY [1][2]. Group 2: Financial Impact - The sale of 3 million shares is expected to increase the company's net profit by approximately 18.55 million CNY after deducting costs and related transaction taxes [2]. - The company still holds 34,465,700 shares of Beijng Beilu Pharmaceutical, representing 6.12% of its total share capital [2].

Core Viewpoint - The company, Yuzhong Sanxia A, announced the sale of 3 million shares of Beilu Pharmaceutical, which is expected to increase net profit by approximately 18.55 million yuan after deducting costs and related transaction taxes [1] Financial Impact - The estimated increase in net profit from the sale of shares is about 18.55 million yuan, subject to final audit by the accounting firm for the impact on the company's net profit in 2026 [1]

股票代码：300016 股票简称：北陆药业 公告编号：2026-010 北京北陆药业股份有限公司 关于持股5%以上股东减持股份计划实施完毕的公告 公司持股5%以上的股东重庆三峡油漆股份有限公司保证向公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 北京北陆药业股份有限公司（以下简称"公司"）于2025年10月25日在巨 潮资讯网披露了《关于持股5%以上股东减持股份的预披露公告》(公告编号： 2025-108)，持有公司股份3,746.57万股（占公司总股本比例6.66%）的股东重 庆三峡油漆股份有限公司（以下简称"三峡油漆"）计划自公告披露之日起15 个交易日后的3个月内，以集中竞价、大宗交易或两者相结合的方式减持不超 过1,000万股公司股份（占公司总股本比例1.78%）。 近日，公司收到三峡油漆出具的《关于股份减持计划实施完毕的告知函》。 截至本公告日，三峡油漆通过集中竞价交易方式累计减持300万股公司股份， 占公司总股本比例0.53%，本次减持计划已实施完毕。现将具体情况公告如下： | 股东 | 减持 | 股 ...

2026年2月5日，公司发布了2025年度以简易程序向特定对象发行股票的预案（二次修订稿），拟募集资 金1.59亿元用于陆芝葆化药生产车间与智能综合仓库项目建设。发行价格为8.45元/股，需经深圳证券交 易所审核及中国证监会注册后方可实施。 业绩经营情况 经济观察网 北陆药业（300016）发布定增预案，拟募资1.59亿元用于项目建设，同时公司预计2025年净 利润同比大幅增长537.28%至852.26%。此外，公司正积极拓展海外市场并推进产能扩建。 定增股票 2026年1月29日，公司预计2025年全年归属于上市公司股东的净利润为8700万元至1.3亿元，同比增长 537.28%至852.26%。正式年报尚未发布，最终数据以审计结果为准。 产能扩充 根据2026年1月22日的机构调研信息，公司正积极拓展海外市场，对比剂生产线已通过欧盟及巴西认 证，并推进海昌药业原料药产能扩建、沧州三期原料生产项目等，以支撑未来业务增长。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Group 1 - The company has invested 10 million yuan in Beijing Chuangjin Xingye Investment Center (Limited Partnership), holding a stake of 1.9194% [2] - The company has invested 10 million yuan in Beijing Silk Road Science and Technology Innovation Investment Center (Limited Partnership), holding a stake of 1.8758% [2] - The company has invested 25 million yuan in Ningbo Meishan Free Trade Port Area Huagai Lisheng Equity Investment Partnership (Limited Partnership), holding a stake of 7.7879% [2]

Core Viewpoint - The article discusses the performance of the A-share market, highlighting the fluctuations in major indices and the notable movements in specific sectors such as media and pharmaceuticals. Market Performance - The Shanghai Composite Index decreased by 0.02% to 4122.34, while the Shenzhen Component Index also fell by 0.02% to 14206.26. The ChiNext Index dropped by 0.14% to 3328.02, and the Sci-Tech Innovation Board Index rose by 0.19% to 1800.35 [4][12]. - The total trading volume in the Shanghai and Shenzhen markets reached 1.4 trillion yuan, with over 2800 stocks declining [6]. Sector Highlights - The media sector experienced significant gains, with multiple stocks such as Light Media and China Film hitting the daily limit, and Huace Film and Happiness Blue Sea rising over 15% [5][6]. - The innovative drug concept saw a surge, with stocks like Guangsheng Tang increasing by over 13% [6]. - The semiconductor sector also performed well, with stocks like Chipone Technology rising over 8% [10]. New Listings - Three new stocks were listed, with N Electric Technology opening at a remarkable increase of 750.05% on its first day [11]. Other Market Movements - The precious metals, shipping, and liquor sectors showed weakness, contrasting with the strong performance of the media and innovative drug sectors [5][6].

Group 1 - The company, Beilu Pharmaceutical, announced that its ninth board meeting was held on February 5, 2026, combining in-person and communication methods [1] - The meeting reviewed the proposal regarding the results of the simplified procedure for issuing stocks to specific targets for the year 2025 [1]

股票代码：300016 股票简称：北陆药业 公告编号：2026-006 北京北陆药业股份有限公司 第九届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第九届董事会第八次会议于2026年 2月5日下午以现场及通讯相结合的方式召开，会议通知以邮件方式送达各位董事。本次会 议应出席董事9人，实际出席董事9人，实际参加表决董事9人。本次会议的召集召开程序 符合《公司法》和《公司章程》的有关规定。会议由董事长王旭先生主持，与会董事以记 名投票方式审议通过了以下议案： 一、关于公司 2025 年度以简易程序向特定对象发行股票竞价结果的议案 根据《公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券 发行注册管理办法》《深圳证券交易所上市公司证券发行与承销业务实施细则》等法律、 法规和规范性文件的有关规定及公司2024年年度股东会的授权，公司及保荐人（主承销商） 中信建投证券股份有限公司于2026年1月29日向符合条件的投资者发送了《北京北陆药业 股份有限公司以简易程序向特定对象 ...

股票代码：300016 股票简称：北陆药业 公告编号：2026-009 北京北陆药业股份有限公司 关于以简易程序向特定对象发行股票摊薄即期回报及 采取填补措施和相关主体承诺（二次修订稿）的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作的意见》 （国办发[2013]110号）、《国务院关于进一步促进资本市场健康发展的若干意见》（国发 [2014]17号）和《关于首发及再融资、重大资产重组摊薄即期回报有关事项的指导意见》（中 国证监会公告[2015]31号）等文件的有关规定，为维护中小投资者利益，北京北陆药业股份 有限公司（以下简称"公司"）就本次以简易程序向特定对象发行股票事宜对即期回报摊 薄的影响进行了分析并提出了具体的填补回报措施，相关主体对公司填补回报措施能够得 到切实履行作出了承诺，具体如下： 一、本次以简易程序向特定对象发行股票摊薄即期回报对公司主要财务指标的影响 （一）主要假设 以下假设仅为测算本次发行摊薄即期回报对公司主要财务指标的影响，不代表对公司 未来经营情况及趋势的判断 ...